Publications

 


  • 586. Differences among men on active surveillance for very low-risk prostate cancer detected through population-based versus opportunistic prostate-specific antigen-screening.

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Recker F, Kwiatkowski M, 2015

    Journal: Urol Int.
    Reference: 94(3):330-6.

  • 585. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial.

    Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A, 2015

    Journal: Prostate
    Reference: Jun 12.

  • 584. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants.

    Yen AM, Auvinen A, Schleutker J, Wu YY, Fann JC, Tammela T, Chen SL, Chiu SY, Chen HH, 2015

    Journal: Prostate
    Reference: Jun;75(8):825-35.

  • 583. Ethnicity and prostate cancer: the way to solve the screening problem?

    Bokhorst LP, Roobol MJ, 2015

    Journal: BMC Med.
    Reference: Aug 4;13:179

  • 582. Early detection of prostate cancer–recommendations after 13 years of follow-up in the European randomised study

    Schröder FH, Roobol MJ, Bangma CH, 2015

    Journal: Ned Tijdschr Geneeskd.
    Reference: 159:A8677.

  • 581. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.

    Venderbos LD1, Roobol MJ, Bangma CH, van den Bergh RC, Bokhorst LP, Nieboer D, Godtman R, Hugosson J, van der Kwast T, Steyerberg EW, 2015

    Journal: World J Urol.
    Reference: Jul 10.

  • 580. Prostate cancer screening in Europe – Authors’ reply.

    Schröder F, Hugosson J, Carlsson S, Moss S, Roobol M, Auvinen A, 2015

    Journal: Lancet
    Reference: Apr 18;385(9977):1507-8

  • 579. Corrigendum to “Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial” [Eur Urol 2013;64:703-9].

    Bergdahl AG, Holmberg E, Moss S, Hugosson J, 2015

    Journal: Eur Urol
    Reference: Aug;68(2):e46.

  • 578. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

    Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M, 2015

    Journal: Eur Urol.
    Reference: Mars 16

  • 577. Is further screening of men with baseline PSA < 1ng/ml worthwhile? the discussion continues – results of the Swiss ERSPC (Aarau).

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Kluth LA, Wyler SF, Recker F, Kwiatkowski M, 2015

    Journal: Int J Cancer
    Reference: Aug 1;137(3):553-9.

  • 576. Prostate cancer screening: and yet it moves!

    Kwiatkowski M, Randazzo M, Kluth L, Manka L, Huber A, Recker F, 2015

    Journal: Asian J Androl
    Reference: May-Jun;17(3):437-8.

  • 575. The Finnish prostate cancer screening trial: Analyses on the screening failures.

    Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A, 2015

    Journal: Int J Cancer
    Reference: May 15;136(10):2437-43.

  • 574. Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial.

    Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J., 2014

    Journal: Eur Urol
    Reference: Dec 31.

  • 573. Reply from Authors re: Sigrid V. Carlsson, Peter C. Albertsen. Better Survival After Curative Treatment for Screen-detected Prostate Cancer Compared with Clinical Diagnosis: A Real Effect or Lead-time Bias? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.10.035: Better Treatment in the Control Arm of the ERSPC Rotterdam: A Point Worth Noting?

    Bokhorst LP, Roobol MJ, Kranse R, 2014

    Journal: Eur Urol
    Reference: Nov 20.

  • 572. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

    Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ, 2014

    Journal: Eur Urol
    Reference: Dec;66(6):1109-15.

  • 571. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

    Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, de Koning HJ, 2014

    Journal: J Natl Cancer Inst
    Reference: Dec 13;107(1):366.

  • 570. Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam.

    Bokhorst LP, Kranse R, Venderbos LD, Salman JW, van Leenders GJ, Schröder FH, Bangma CH, Roobol MJ; for the ERSPC Rotterdam Study Group, 2015

    Journal: Eur Urol
    Reference: Aug;68(2):179-82.

  • 569. Influence of metformin use on PSA values, free‑to‑total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau)

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler SF, Chun FF, Recker F, Kwiatkowski M, 2014

    Journal: World J Urol
    Reference: Oct 31

  • 568. Family history in the finnish prostate cancer screening trial.

    Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, Auvinen A, 2015

    Journal: Int J Cancer.
    Reference: May 1;136(9):2172-7.

  • 567. Prostate cancer: Rescreening policies and risk calculators.

    Roobol MJ, 2014

    Journal: Nat Rev Urol.
    Reference: Aug;11(8):429-30.

  • 566. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

    Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; for the ERSPC Investigators, 2014

    Journal: Lancet.
    Reference: Aug 6.

  • 565. Screening for prostate cancer: current status of ERSPC and screening-related issues.

    Schröder FH., 2014

    Journal: Recent Results Cancer Res.
    Reference: 202:47-51.

  • 564. Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores >=100.

    Schröder FH, Venderbos LD, van den Bergh RC, Hessels D, van Leenders GJ, van Leeuwen PJ, Wolters T, Barentsz JO, Roobol MJ., 2014

    Journal: Urology
    Reference: Mar;83(3):613-6.

  • 563. International perspectives on screening.

    Roobol MJ., 2014

    Journal: Urol Clin North Am
    Reference: May;41(2):237-47.

  • 562. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.

    Wilt TJ, Scardino PT, Carlsson SV, Basch E., 2014

    Journal: J Natl Cancer Inst.
    Reference: Mar;106(3):dju010.

  • 561. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

    Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A., 2014

    Journal: BMJ
    Reference: Mar 28;348:g2296.

  • 560. A “PSA Pyramid” for Men with Initial Prostate-specific Antigen ≤3 ng/ml: A Plea for Individualized Prostate Cancer Screening.

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M., 2014

    Journal: Eur Urol
    Reference: 14-04-18

  • 559. Overdiagnosis and Overtreatment of Prostate Cancer.

    Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R, 2014

    Journal: Eur Urol
    Reference: Jan 9. pii: S0302-2838(13)01490-5.

  • 558. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

    Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H, 2014

    Journal: BMC Med
    Reference: Feb 11;12:26.

  • 557. RE: Prostate-Specific Antigen Screening Trials and Prostate Cancer Deaths: The Androgen Deprivation Connection.

    Carlsson S, Roobol MJ, Schröder FH, Hugosson J, Auvinen A, 2014

    Journal: J Natl Cancer Inst
    Reference: Apr 26;106(5).

  • 556. Overdetection in screening for prostate cancer.

    Hugosson J, Carlsson S, 2014

    Journal: Curr Opin Urol
    Reference: May;24(3):256-63.

  • 555. Prostate cancer incidence and mortality in the Spanish section of the European Randomized Study of Screening For Prostate Cancer (ERSPC).

    Luján M, Páez A, Angulo JC, Granados R, Nevado M, Torres GM, Berenguer A., 2014

    Journal: Prostate Cancer Prostatic Dis
    Reference: Jun;17(2):187-91.

  • 554. ERSPC, PLCO studies and critique of cochrane review 2013.

    Schröder, 2014

    Journal: Recent Results Cancer Res
    Reference: 202:59-63.

  • 553. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.

    Yli-Hemminki TH, Laurila M, Auvinen A, Määttänen L, Huhtala H, Tammela TL, Kujala PM, 2013

    Journal: BJU Int
    Reference: 112: 735–741.

  • 552. Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial. (ERSPC)

    Vasarainen H, Malmi H, Määttänen L, Ruutu M, Tammela T, Taari K, Rannikko A, Auvinen A, 2013

    Journal: Acta Oncologica
    Reference: 52: 1615–1621.

  • 551. The Rate of Overdiagnosis Inextricably Linked to Prostate-specific Antigen-Based Screening for Prostate Cancer Can Be Quantified in Several Ways, But What Is the Practicable Message?

    Roobol MJ, Schröder FH, 2014

    Journal: Eur Urol
    Reference: 14-01-24

  • 550. A Different Method of Evaluation of the ERSPC Trial Confirms That Prostate-specific Antigen Testing Has a Significant Impact on Prostate Cancer Mortality.

    Zappa M, Puliti D, Hugosson J, Schröder FH, van Leeuwen PJ, Kranse R, Auvinen A, Carlsson S, Kwiatkowski M, Nelen V, Borda AP, Roobol MJ, Villers A, 2014

    Journal: Eur Urol
    Reference: 14-01-07

  • 549. Reply from Authors re: Chris Metcalfe. Can the Results of the European Randomized Study of Screening for Prostate Cancer Be Decontaminated? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.08.058: Yes, by Remaining Conservative in Our Assumptions.

    Bokhorst LP, Moss SM, Roobol MJ, 2014

    Journal: Eur Urol
    Reference: Feb;65(2):338-9.

  • 548. Reply from Authors re: Michael Baum. Screening for Prostate Cancer: Can We Learn from the Mistakes of the Breast Screening Experience? Eur Urol 2013;64:540-1: Screening for Prostate Cancer: We Have Learned and Are Still Learning.

    Roobol MJ, Kranse R, Bangma CH, Otto SJ, van der Kwast TH, Bokhorst LP, de Koning HJ, Schröder FH, 2013

    Journal: Eur Urol
    Reference: Oct;64(4):541-3.

  • 547. Prostate-specific Antigen-Based Prostate Cancer Screening: Reduction of Prostate Cancer Mortality After Correction for Nonattendance and Contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer.

    Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, Roobol MJ, 2014

    Journal: Eur Urol
    Reference: 65(2):329-36.

  • 546. Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC)

    Van der Kwast T, Bubendorf L, Mazerolles C, Raspollini MR, Van Leenders GJ, Pihl CG, Kujala P, 2013

    Journal: Virchows Arch
    Reference: Sep;463(3):367-77.

  • 545. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

    Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H, 2013

    Journal: Thromb Haemost
    Reference: Aug 1;110(3).

  • 544. Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death.

    Nurminen R, Lehtonen R, Auvinen A, Tammela TL, Wahlfors T, Schleutker J, 2013

    Journal: Eur J Cancer
    Reference: Oct;49(15):3335-43.

  • 543. The prostate-specific antigen test.

    Roobol MJ, 2013

    Journal: Expert Opin Med Diagn.
    Reference: Sep;7(5):423-6.

  • 542. General practitioner (GP)’s view on screening for prostate cancer in the Netherlands: the impact of a randomized trial.

    Schröder F, 2013

    Journal: BJU Int
    Reference: Jul;112(1):4-5.

  • 541. Reply from Authors re: H. Ballentine Carter. Prostate-specific Antigen-Based Screening for Prostate Cancer: The Irony of It All. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.06.004: Should Men Older than Age 70 Be Recommended Against Screening?

    Bergdahl AG, Hugosson J, 2013

    Journal: Eur Urol
    Reference: Nov;64(5):711-2.

  • 540. Reply from Authors re: Michael Baum. Screening for Prostate Cancer: Can We Learn from the Mistakes of the Breast Screening Experience? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.053: Screening for Prostate Cancer: We Have Learned and Are Still Learning.

    Roobol MJ, Kranse R, Bangma CH, Otto SJ, van der Kwast TH, Bokhorst LP, de Koning HJ, Schröder FH, 2013

    Journal: Eur Urol
    Reference: Oct;64(4):541-3.

  • 539. Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier method.

    Zhu X, Kranse R, Bul M, Bangma CH, Schröder FH, Roobol MJ., 2013

    Journal: Can J Urol
    Reference: Jun;20(3):6756-60.

  • 538. Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer.

    Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; the ERSPC Rotterdam study group., 2013

    Journal: Eur Urol
    Reference: Oct;64(4):530-9.

  • 537. Defining the threshold for significant versus insignificant prostate cancer.

    Van der Kwast TH, Roobol MJ, 2013

    Journal: Nat Rev Urol
    Reference: Aug;10(8):473-82.

Next →